An update on peripheral blood progenitor cell transplantation

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• High-dose therapy with stem cell rescue is a key treatment for poor-risk malignant diseases.
• Peripheral blood progenitor cells (PBPC) offer an alternative to bone marrow transplantation, potentially reducing toxicity.
• Mobilization and collection methods for PBPC are areas of ongoing research and debate.

Purpose of the Study:

• To review the current status and therapeutic perspectives of peripheral blood progenitor cells (PBPC) in high-dose therapy.
• To compare engraftment and clinical outcomes of mobilized PBPC with autologous bone marrow transplantation.
• To discuss advancements in PBPC collection, processing, and their role in allogeneic transplantation.

Main Methods:

• Review of existing studies comparing PBPC transplantation with autologous bone marrow transplantation.
• Analysis of techniques for PBPC collection (steady state, chemotherapy, growth factor priming).
• Examination of methods for tumor cell reduction and CD34-positive cell selection.

Main Results:

• Mobilized PBPC show beneficial effects on neutrophil and platelet engraftment compared to autologous bone marrow.
• Accelerated hematological recovery with PBPC is associated with reduced platelet transfusions and shorter hospital stays.
• Techniques for tumor cell purging and CD34 selection are being developed for improved safety and efficacy.

Conclusions:

• PBPC transplantation accelerates hematological recovery and offers clinical benefits in high-dose therapy.
• Advancements in cell selection techniques are crucial for optimizing PBPC use in transplantation and gene therapy.
• The role of PBPC in allogeneic transplantation is under active investigation.